Skip to content

US · PRTA · BIOTECHNOLOGY

Prothena Corporation plc (PRTA) intrinsic value and stock valuation

$8.22as of 2026-11-21 · Mkt cap 444.48M

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Prothena Corporation plc DCF and intrinsic value

InvestorsCraft values PRTA with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from PRTA’s statements →

Prothena Corporation plc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Dublin, DU D02 VK60 prothena.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$9.68M+62.7% 5y CAGRd
20112025
Net income
-$-244.09M
20112025
Free cash flow
-$-163.72M
20112025
Total equity
$280.5M+8.8% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$9.68M$135.2M$91.4M$53.9M$200.6M
Operating income-$-184.56M-$-154.56M-$-191.04M-$-131.56M$72M
Net income-$-244.09M-$-122.31M-$-147.03M-$-116.95M$67M
EPSd-$-4.53M-$-2.27M-$-2.76M-$-2.47M$1.38M
Operating cash flow-$-163.58M-$-150.05M-$-133.91M-$-108.82M$92.6M
Capital expenditure-$-140K-$-300K-$-2.81M-$-460K-$-570K
Free cash flow-$-163.72M-$-150.35M-$-136.72M-$-109.28M$92M
Total assets$326.8M$547.1M$696.4M$758M$609.4M
Total debt$13.9M$10.8M$11.8M$6.47M$12.3M
Net debt-$-293.67M-$-460.55M-$-607M-$-703.93M-$-566.77M
Total equity$280.5M$486.9M$561.4M$622M$466M
Cash and short-term investments$307.5M$471.4M$618.8M$710.4M$579.1M
Income statement
20252024202320222021
Revenue$9.68M$135.2M$91.4M$53.9M$200.6M
Cost of revenue$3.7M$0.00$0.00$0.00$0.00
Gross profit$5.98M$135.2M$91.4M$53.9M$200.6M
Research and development expenses$134.9M$222.5M$220.6M$135.6M$82.3M
Selling, general and administrative expenses$59.4M$67.2M$61.8M$49.9M$46.3M
Other expenses-$-3.7M$0.00$0.00$0.00$0.00
Operating expenses$190.5M$289.7M$282.4M$185.5M$128.6M
Cost and expenses$194.2M$289.7M$282.4M$185.5M$128.6M
Interest income$14.1M$25.8M$31M$6.35M$40K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$3.7M$890K$930K$740K$1.11M
Ebitda-$-197.13M-$-128.04M-$-159.55M-$-124.86M$73M
Operating income-$-184.56M-$-154.56M-$-191.04M-$-131.56M$72M
Total other income/expenses, net-$-16.27M$25.6M$30.6M$5.95M-$-50K
Income before tax-$-200.83M-$-128.93M-$-160.48M-$-125.61M$71.9M
Income tax expense$43.3M-$-6.62M-$-13.45M-$-8.66M$4.95M
Net income-$-244.09M-$-122.31M-$-147.03M-$-116.95M$67M
Weighted average shares outstanding$53.8M$53.8M$53.2M$47.4M$44.2M
Weighted average diluted shares outstanding$53.8M$53.8M$53.2M$47.4M$48.5M
Balance sheet
20252024202320222021
Cash and short-term investments$307.5M$471.4M$618.8M$710.4M$579.1M
Net receivables$0.00$0.00$5.16M$60K$10K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$315.2M$485.4M$639.3M$719.1M$584.8M
Property, plant and equipment, net$10.3M$13.8M$16M$8.01M$14.1M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$860K$860K$0.00$0.00$0.00
Total non-current assets$11.6M$61.7M$57.1M$38.9M$24.6M
Total assets$326.8M$547.1M$696.4M$758M$609.4M
Accounts payable$5.88M$7.77M$25.4M$9.27M$3.69M
Short-term debt$2.89M$2.61M$1.11M$6.47M$5.94M
Deferred revenue$2.66M$8.85M$0.00$11.4M$7.66M
Total current liabilities$40.8M$48.5M$56.9M$50.2M$33.5M
Long-term debt$11M$8.23M$10.7M$0.00$6.39M
Deferred revenue, non-current$0.00$3.45M$67.4M$85.3M$102.9M
Total non-current liabilities$5.49M$11.7M$78.1M$85.9M$109.9M
Capital lease obligations$5.49M$10.8M$11.8M$6.47M$12.3M
Total liabilities$46.3M$60.2M$135M$136M$143.3M
Common stock$540K$540K$540K$520K$470K
Retained earnings-$-1.35B-$-1.1B-$-980.03M-$-833M-$-716.05M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$280.5M$486.9M$561.4M$622M$466M
Total investments$860K$860K$0.00$0.00$0.00
Total debt$13.9M$10.8M$11.8M$6.47M$12.3M
Net debt-$-293.67M-$-460.55M-$-607M-$-703.93M-$-566.77M
Cash flow statement
20252024202320222021
Net income-$-244.09M-$-122.31M-$-147.03M-$-116.95M$67M
Depreciation and amortization$900K$890K$930K$740K$1.11M
Stock-based compensation$37.6M$46M$40.9M$31.3M$24.7M
Change in working capital-$-4.17M-$-67.94M-$-20.53M-$-18.8M-$-10.4M
Accounts receivable$0.00$5.16M-$-5.16M$0.00$10K
Inventory$0.00$0.00-$-8.9M$0.00$0.00
Accounts payable-$-15.78M-$-18.3M$22.9M$11.9M-$-490K
Net cash provided by operating activities-$-163.58M-$-150.05M-$-133.91M-$-108.82M$92.6M
Investments in property, plant and equipment-$-140K-$-300K-$-2.81M-$-460K-$-570K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-140K-$-300K-$-2.77M-$-460K-$-570K
Common stock issued-$-140K$0.00$23.6M$223.6M$174.8M
Common stock repurchased$0.00-$-350K$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-140K$1.55M$45.1M$241.5M$190.3M
Net change in cash-$-163.86M-$-148.79M-$-91.58M$132.2M$282.4M
Cash at end of period$308.4M$472.3M$621M$712.6M$580.5M
Operating cash flow-$-163.58M-$-150.05M-$-133.91M-$-108.82M$92.6M
Capital expenditure-$-140K-$-300K-$-2.81M-$-460K-$-570K
Free cash flow-$-163.72M-$-150.35M-$-136.72M-$-109.28M$92M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Prothena Corporation plc

        Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

        CEO
        Gene G. Kinney
        Employees
        67
        Beta
        -0.35

        Explore

        Frequently asked questions

        What is the intrinsic value of Prothena Corporation plc (PRTA)?

        Prothena Corporation plc (PRTA) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is PRTA undervalued?

        PRTA trades at a price of $8.22 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.